Expanding the drug discovery platform and rare disease portfolio through the acquisition of Jnana Therapeutics
First written in FY2024-H1. 1 of 2 entries say "Achieved", first in FY2024. Latest entry: FY2024.
No other company in this theme has enough history to compare yet.
- FY2024AchievedAnnual report
「Otsuka Pharmaceutical agreed on 19 September 2024 to acquire Jnana Therapeutics Inc., a US-based pharmaceutical research and development company, as a wholly owned subsidiary and entered into an agreement to that effect.」
The acquisition of Jnana as a wholly owned subsidiary was completed on 19 September 2024, bringing the RAPID drug discovery platform, JNT-517 and a small-molecule pipeline focused on autoimmune diseases and other conditions into the Group. - FY2024-H1First statedAnnual report
「Otsuka Pharmaceutical agreed and entered into an agreement on 1 August 2024 to make Jnana Therapeutics Inc., a US-based pharmaceutical research and development company, a wholly owned subsidiary through a share acquisition followed by a merger conducted via an acquisition vehicle established by Otsuka America Inc., with consideration consisting of cash and future milestone payments.」
The Company entered into an agreement to make Jnana, which has its proprietary RAPID drug discovery platform, the phenylketonuria drug candidate JNT-517 and a small-molecule pipeline for autoimmune and other diseases, a wholly owned subsidiary. Completion was planned for the third quarter of fiscal 2024, with consideration of US$800 million payable upon acquisition and up to US$325 million in development and regulatory milestones.